loader2
Partner With Us NRI

Company details

93.10
96.10
87.50
148.50
6M Return -16.40%
1Y Return -9.90%
Mkt Cap.(Cr) 145.29
Volume 2,443
Div Yield 1.01%
OI
-
OI Chg %
-
Volume 2,443

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 57.69 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 14,815.21 -9,586.34
LAST 3M 17,872.86 35,101.17
LAST 6M 91,463.43 -68,898.33
LAST 12M 211,994.84 -206,912.16
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
Sep 13, 2022 Dividend 10
Sep 16, 2021 Dividend 10

Information

  • About Company
  • Company Info
  • Listing Info
34.36
52%
39.4539
11.02%
9.04%
Description
  • Bal Pharma (BPL), a member of the Mcro Laboratories group, was incorporated as a private limited company in May `87. In Mar.`90, BPL took over a pharmaceutical products manufacturing unit located in Bangalore through the Karnataka State Finance Corporation for a consideration of Rs 25.18 lac following which, BPL commenced manufacturing formulations. BPL manufactures and markets pharmaceutical formulations -- paracetamol, aluminium hydroxide, povidone iodine, alprazolam, gliclazide, griseofulvin, lactobacillus, rifampicin, piroxicam amoxycillin, etc. The company promotes its products through the common sales force of the group but proposes to induct its own soon. It came out with a public issue in Feb.`95 for manufacture of bulk drugs and expansion of pharmaceutical formulations. During 1997-98, the formalities of takeover of the unit from Lakme Limited have been completed and effective from 23rd July, 1997 the unit has become a division of Bal Pharma Limited. The company`s product range has been expanded with the introduction of AZIWIN, CAFIMOL & CORTIDERM. The company has added further product range Zanovid, Aziwin, Dry Syrup, Meloxi, Ocium - M, Progit - MPS in its ethical division during 1999-2000. As part of the expansion of the product range, the company has introduced Cardiac Specialities Products. To market these products, a new division named "SERVETUS" has started functioning during 2001. New products like Amiloride,Benzydamine and Ebastine were rolled into the market during 2002.

Read More

Registered Address

21 & 22 Bommasandra Indl Area, Hosur Road, Bangalore, Karnataka, 560092

Email : secretarial:balpharma.com/info:balpharma.com
Website : http://www.balpharma.com

Registrar

TSR Consultants P Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524824
NSE Code : BALPHARMA
Book Closure Date (Month) : Sep
BSE Group : T
ISIN : INE083D01012

ICICIdirect Bal Pharma Ltd FAQ

You can buy Bal Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Bal Pharma Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of Sep 30, 2022 04:01 PM the closing price of Bal Pharma Ltd was ₹ 93.30.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Sep 30, 2022 04:01 PM, the market cap of Bal Pharma Ltd stood at ₹ 145.29.
The latest PE ratio of Bal Pharma Ltd as of Sep 30, 2022 04:01 PM is 34.36
The latest PB ratio of Bal Pharma Ltd as of Sep 30, 2022 04:01 PM is 0.42
The 52-week high of Bal Pharma Ltd is ₹ 148.50 while the 52-week low is ₹ 87.50 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE